Lapatinib Combined With Paclitaxel For Patients With First-Line ErbB2-Amplified Metastatic Breast Cancer
Status:
Completed
Trial end date:
2013-12-01
Target enrollment:
Participant gender:
Summary
This study investigates the safety and efficacy of oral lapatinib in combination with an
approved medication, paclitaxel, for patients with ErbB2 metastatic breast cancer.